Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (31)

2024

  1. Localization, traffic and function of Rab34 in adipocyte lipid and endocrine functions

    Journal of Biomedical Science, Vol. 31, Núm. 1

2023

  1. Hepatic p63 regulates glucose metabolism by repressing SIRT1

    Gut, Vol. 72, Núm. 3, pp. 472-483

  2. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

    Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5

2021

  1. Long-term prognosis of women with Brugada syndrome and electrophysiological study

    Heart Rhythm, Vol. 18, Núm. 5, pp. 664-671

2018

  1. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Journal of Controlled Release, Vol. 276, pp. 125-139

2016

  1. Risk of pacemaker implantation after uneventful successful cavotricuspid isthmus radiofrequency ablation in patients with common atrial flutter

    International Journal of Cardiology, Vol. 202, pp. 285-288

2015

  1. Registro Español de Trasplante Cardiaco (Adultos). XXV Informe Oficial de la Sección de Insuficiencia Cardiaca y Trasplante Cardiaco de la Sociedad Española de Cardiología (1984-2013)

    Revista Espanola de Cardiologia Suplementos, Vol. 15, Núm. S2, pp. 31-42

  2. Targeting γ-secretases protect against angiotensin II-induced cardiac hypertrophy

    Journal of Hypertension

2014

  1. The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole

    Neurodegenerative Diseases, Vol. 13, Núm. 2-3, pp. 171-179

2013

  1. Dislipidemia en población diabé tica tratada con estatinas. Resultados del Dyslipidemia International Study en España

    Medicina Clinica, Vol. 141, Núm. 10, pp. 430-436

2011

  1. Anticoagulation prescription in atrial fibrillation

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 10, pp. 1473-1479

  2. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study

    Revista Espanola de Cardiologia, Vol. 64, Núm. 4, pp. 286-294

2010

  1. Extracellular fatty acid synthase: A possible surrogate biomarker of insulin resistance

    Diabetes, Vol. 59, Núm. 6, pp. 1506-1511

2009

  1. Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study

    Medicina Clinica, Vol. 132, Núm. 8, pp. 291-297

  2. Hypothalamic lipids and the regulation of energy homeostasis

    Obesity Facts, Vol. 2, Núm. 2, pp. 126-135

  3. Larrad biliopancreatic diversion in sprague-dawley rats. Analysis of weight loss related to food intake

    Obesity Surgery, Vol. 19, Núm. 4, pp. 484-489

2008

  1. Estudio PET-TC con 18F-fluoro-L-DOPA combinado con el análisis genético para la optimización de la clasificación y tratamiento de un niño con hiperinsulinismo congénito grave

    Anales de Pediatria, Vol. 68, Núm. 5, pp. 481-485

  2. Heart failure in outpatients: Comorbidities and management by different specialists. The EPISERVE study

    Revista Espanola de Cardiologia, Vol. 61, Núm. 6, pp. 611-619

2007

  1. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring

    Clinical Drug Investigation, Vol. 27, Núm. 6, pp. 407-417

  2. Control de los factores de riesgo cardiovascular en el paciente hipertenso con disfunción cardíaca: Atención Primaria frente a Especializada

    Hipertension, Vol. 24, Núm. 4, pp. 148-156